1445385-02-3|卢米西他滨|Lumicitabine|No data available-范德生物科技公司

卢米西他滨

NMR下载 COA and HPLC MSDS下载
names：
Lumicitabine
CAS号：
1445385-02-3
MDL Number： No data available
MF(分子式)： C18H25ClFN3O6 MW(分子量)： 433.86
EINECS:No data available Reaxys Number:No data available
Pubchem ID:89658382 Brand:BIOFOUNT

卢米西他滨(1445385-02-3,Lumicitabine)是呼吸道合胞病毒（RSV）聚合酶的抑制剂。Lumicitabine可转化为血浆循环型ALS-8112，然后转化为宿主细胞内的5'-活性三磷酸核苷（NTP）形式。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000870-5mg	5mg	99%	¥ 3543.00	¥ 3543.00		2-3天	- +	¥ 0.00
YZM000870-1mg	1mg	99%	¥ 1462.00	¥ 1462.00		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	卢米西他滨(1445385-02-3,Lumicitabine);ALS-8176;ALS-008176
英文别名	Lumicitabine(1445385-02-3);ALS-8176;ALS-008176
CAS号	1445385-02-3
SMILES	ClC[C@@]1(COC(C(C)C)=O)[C@@H](OC(C(C)C)=O)[C@@H](F)[C@H](N2C(N=C(N)C=C2)=O)O1
Inchi	InChI=1S/C18H25ClFN3O6/c1-9(2)15(24)27-8-18(7-19)13(28-16(25)10(3)4)12(20)14(29-18)23-6-5-11(21)22-17(23)26/h5-6,9-10,12-14H,7-8H2,1-4H3,(H2,21,22,26)/t12-,13+,14-,18-/m1/s1
InchiKey	MJVKYGMNSQJLIN-KYZVSKTDSA-N
分子式 Formula	C18H25ClFN3O6
分子量 Molecular Weight	433.86
闪点 FP	276.4±32.9 °C
熔点 Melting point	No data available
沸点 Boiling point	533.5±60.0 °C at 760 mmHg
Polarizability极化度	39.8±0.5 10-24cm3
密度 Density	1.4±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±1.4 mmHg at 25°C
溶解度Solubility	生物体外In Vitro:DMSO溶解度≥ 50 mg/mL(115.24 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状	白色至灰白色固体粉末
储藏条件 Storage conditions	-20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月

卢米西他滨(1445385-02-3,Lumicitabine)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

Lumicitabine(1445385-02-3) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:卢米西他滨(1445385-02-3,Lumicitabine),Lumicitabine试剂,Lumicitabine抑制剂,Lumicitabine的杂质,Lumicitabine的纯度,Lumicitabine的MSDS,Lumicitabine的作用,Lumicitabine的外观,Lumicitabine的使用,Lumicitabine的合成,Lumicitabine的生产

产品说明	卢米西他滨(1445385-02-3,Lumicitabine)是呼吸道合胞病毒（RSV）聚合酶的抑制剂。
Introduction	Lumicitabine (1445385-02-3,卢米西他滨) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.
Application1
Application2
Application3

Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations).

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

Potent in vitro activity of β-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus PMID 31935422; Antiviral research 2020 03; 175( ):104712

Synthesis of 4'-Substituted-2'-Deoxy-2'-α-Fluoro Nucleoside Analogs as Potential Antiviral Agents PMID 32168734; Molecules (Basel, Switzerland) 2020 Mar; 25(6):

Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans PMID 30376079; The Journal of antimicrobial chemothe

Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference PMID 30974127; Antiviral research 2019 07; 167(?):45-67 (Review Article)

Antiviral treatment of severe non-influenza respiratory virus infection PMID 29095723; Current opinion in infectious diseases 2017 Dec; 30(6):573-578 (Review Article)

Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children
Introduction:The REGAL (RSV Evidence – A Geographical Archive of the Literature) series has provided a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This seventh and final publication covers the past, present and future approaches to the prevention and treatment of RSV infection among infants and children.
Methods:A systematic review was undertaken of publications between January 1, 1995 and December 31, 2017 across PubMed, Embase and The Cochrane Library. Studies reporting data on the effectiveness and tolerability of prophylactic and therapeutic agents for RSV infection were included. Study quality and strength of evidence (SOE) were graded using recognized criteria. A further nonsystematic search of the published literature and Clinicaltrials.gov on antiviral therapies and RSV vaccines currently in development was also undertaken.

Results:The systematic review identified 1441 studies of which 161 were included. Management of RSV remains centered around prophylaxis with the monoclonal antibody palivizumab, which has proven effective in reducing RSV hospitalization (RSVH) in preterm infants < 36 weeks’ gestational age (72% reduction), children with bronchopulmonary dysplasia (65% reduction), and infants with hemodynamically significant congenital heart disease (53% reduction) (high SOE). Palivizumab has also shown to be effective in reducing recurrent wheezing following RSVH (high SOE). Treatment of RSV with ribavirin has conflicting success (moderate SOE). Antibodies with increased potency and extended half-life are currently entering phase 3 trials. There are approximately 15 RSV vaccines in clinical development targeting the infant directly or indirectly via the mother.

Conclusion:Palivizumab remains the only product licensed for RSV prophylaxis, and only available for high-risk infants. For the general population, there are several promising vaccines and monoclonal antibodies in various stages of clinical development, with the aim to significantly reduce the global healthcare impact of this common viral infection.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开